TY - JOUR
T1 - Positron emission tomography and radioimmunotargeting - Aspects of quantification and dosimetry
AU - Lubberink, Mark
AU - Lundqvist, Hans
AU - Westlin, Jan Erik
AU - Tolmachev, Vladimir
AU - Schneider, Harald
AU - Lövqvist, Anna
AU - Sundin, Anders
AU - Carlsson, Jörgen
N1 - Funding Information:
The authors thank the staff at Uppsala University PET Centre and The Svedberg Laboratory for their technical assistance with PET measurements and nuclide production. Financial support was received from the Medical Faculty of Uppsala University, the Swedish Cancer Foundation and the Swedish Medical Research Council.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - Positron emission tomography (PET) is a medical imaging tool with high resolution and good quantitative properties, which makes it suitable for in vivo quantification of radioimmunotargeting agents. Most radionuclides used in radioimmunotherapy have positron-emitting analogues, which can be used for PET imaging, and this opens the possibility of performing dosimetry with PET. These isotopes, however, often emit gamma radiation and high-energy positrons in their decay, influencing the imaging properties of PET. Spatial resolution, reconstructed background and line source recovery for a number of non-pure positron emitters were investigated and compared with the imaging properties of 18F. PET imaging properties did not degrade severely for these non-pure positron emitters, but caution has to be applied when doing quantitative measurements. To assess the possibility of conducting PET studies during therapy, by combining, for example, a small amount of 124I with 131I, the influence of the presence of large amounts of gamma radiation on PET count rate characteristics was studied. The results of these studies were related to the necessary amounts of radioactivity needed for treatment of post-operative remains of glioma. The results indicate that the count rate capabilities of 2D PET permit PET studies for dose evaluation during radioimmunotherapy.
AB - Positron emission tomography (PET) is a medical imaging tool with high resolution and good quantitative properties, which makes it suitable for in vivo quantification of radioimmunotargeting agents. Most radionuclides used in radioimmunotherapy have positron-emitting analogues, which can be used for PET imaging, and this opens the possibility of performing dosimetry with PET. These isotopes, however, often emit gamma radiation and high-energy positrons in their decay, influencing the imaging properties of PET. Spatial resolution, reconstructed background and line source recovery for a number of non-pure positron emitters were investigated and compared with the imaging properties of 18F. PET imaging properties did not degrade severely for these non-pure positron emitters, but caution has to be applied when doing quantitative measurements. To assess the possibility of conducting PET studies during therapy, by combining, for example, a small amount of 124I with 131I, the influence of the presence of large amounts of gamma radiation on PET count rate characteristics was studied. The results of these studies were related to the necessary amounts of radioactivity needed for treatment of post-operative remains of glioma. The results indicate that the count rate capabilities of 2D PET permit PET studies for dose evaluation during radioimmunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0033063908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033063908&partnerID=8YFLogxK
U2 - 10.1080/028418699431429
DO - 10.1080/028418699431429
M3 - Article
C2 - 10380826
AN - SCOPUS:0033063908
VL - 38
SP - 343
EP - 349
JO - Acta Oncologica
JF - Acta Oncologica
SN - 0284-186X
IS - 3
ER -